The Cancer Letter

Inside information on cancer research and drug development

In Brief

MD Anderson Cancer Center partners with GlaxoSmithKline

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MD ANDERSON CANCER CENTER formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing anticancer immunotherapies.

This marks the fourth and final collaboration in a plan to partner with pharmaceutical companies as part of MD Anderson’s Moon Shots Program. GSK and MD Anderson will work to identify therapeutic approaches, evaluate patient responses in clinical trials, and develop immunotherapy drugs.

YOU MAY BE INTERESTED IN

Sponsored

Harnessing innovation: The next frontier in surgical oncology

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
By Yuman Fong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account